|
gptkbp:instance_of
|
gptkb:Skin
|
|
gptkbp:approves
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:brand
|
gptkb:Rhinocort
|
|
gptkbp:category
|
Category B
|
|
gptkbp:class
|
gptkb:Android
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
seasonal allergies
perennial allergies
|
|
gptkbp:community_service
|
approved for children over 6 years
|
|
gptkbp:contraindication
|
hypersensitivity to budesonide
untreated fungal infections
|
|
gptkbp:dosage_form
|
spray
32 mcg per spray
64 mcg per spray
|
|
gptkbp:drug_interactions
|
CYP3 A4 inhibitors
|
|
gptkbp:duration
|
as needed
|
|
gptkbp:effective_date
|
gptkb:1997
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_support
|
shake well before use
|
|
gptkbp:formulation
|
suspension
aqueous
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rhinocort
|
|
gptkbp:indication
|
treatment of nasal symptoms
|
|
gptkbp:ingredients
|
gptkb:budesonide
|
|
gptkbp:is_effective_against
|
improves quality of life
reduces nasal congestion
|
|
gptkbp:lifespan
|
2.5 hours
|
|
gptkbp:manufacturer
|
gptkb:Astra_Zeneca
|
|
gptkbp:marketed_as
|
Rhinocort Aqua
Rhinocort Turbuhaler
|
|
gptkbp:mechanism_of_action
|
anti-inflammatory
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_population
|
adults and children
|
|
gptkbp:pharmacokinetics
|
rapid absorption
local effect on nasal mucosa
|
|
gptkbp:provides_guidance_on
|
recommended for moderate to severe symptoms
|
|
gptkbp:route_of_administration
|
intranasal
|
|
gptkbp:safety
|
not for use in children under 6 years
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
once daily
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
cough
nosebleeds
dysgeusia
throat irritation
nasal irritation
dryness of the nasal mucosa
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
nasal polyps
allergic rhinitis
|
|
gptkbp:bfsParent
|
gptkb:budesonide
|
|
gptkbp:bfsLayer
|
6
|